These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23083820)

  • 1. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.
    Berger CT; Kim AY
    Infect Dis Clin North Am; 2012 Dec; 26(4):863-77. PubMed ID: 23083820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL28B and the control of hepatitis C virus infection.
    Balagopal A; Thomas DL; Thio CL
    Gastroenterology; 2010 Dec; 139(6):1865-76. PubMed ID: 20950615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.
    Bellanti F; Vendemiale G; Altomare E; Serviddio G
    Clin Dev Immunol; 2012; 2012():849373. PubMed ID: 22966241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL28B single nucleotide polymorphisms in the treatment of hepatitis C.
    Lange CM; Zeuzem S
    J Hepatol; 2011 Sep; 55(3):692-701. PubMed ID: 21440591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?
    Orlent H; Reynaert H; Bourgeois S; Dideberg V; Adler M; Colle I; De Maeght S; Laleman W; Michielsen P; Moreno C; Mulkay JP; Stärkel P; Delwaide J;
    Acta Gastroenterol Belg; 2011 Jun; 74(2):317-22. PubMed ID: 21861317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.
    Jiménez-Sousa MA; Fernández-Rodríguez A; Guzmán-Fulgencio M; García-Álvarez M; Resino S
    BMC Med; 2013 Jan; 11():6. PubMed ID: 23298311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.
    Alestig E; Arnholm B; Eilard A; Lagging M; Nilsson S; Norkrans G; Wahlberg T; Wejstål R; Westin J; Lindh M
    BMC Infect Dis; 2011 May; 11():124. PubMed ID: 21569441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of IL28B and HCV--response to infection and treatment.
    Hayes CN; Imamura M; Aikata H; Chayama K
    Nat Rev Gastroenterol Hepatol; 2012 May; 9(7):406-17. PubMed ID: 22641049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.
    de Castellarnau M; Aparicio E; Parera M; Franco S; Tural C; Clotet B; Martínez MA
    PLoS One; 2012; 7(2):e31016. PubMed ID: 22328925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.
    Jia Z; Ding Y; Tian S; Niu J; Jiang J
    PLoS One; 2012; 7(9):e45698. PubMed ID: 23029188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.
    Asthana M; Sahu SK; Kumar A; Mohanty S; Chakrabarti S; Das P; Chattopadhya NR; Chatterjee K; Singh SP; Rajasubramaniam S; Choudhuri T
    Curr Drug Metab; 2018; 19(3):215-223. PubMed ID: 29380700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients.
    El Awady MK; Bader El Din NG; Tabll A; El Hosary Y; Abdel Aziz AO; El Khayat H; Salama M; Abdelhafez TH
    World J Gastroenterol; 2013 Jan; 19(2):290-8. PubMed ID: 23345953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.
    Thomas DL; Thio CL; Martin MP; Qi Y; Ge D; O'Huigin C; Kidd J; Kidd K; Khakoo SI; Alexander G; Goedert JJ; Kirk GD; Donfield SM; Rosen HR; Tobler LH; Busch MP; McHutchison JG; Goldstein DB; Carrington M
    Nature; 2009 Oct; 461(7265):798-801. PubMed ID: 19759533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
    Laird ME; Mohsen A; Duffy D; Mamdouh R; LeFouler L; Casrouge A; El-Daly M; Rafik M; Abdel-Hamid M; Soulier A; Pawlotsky JM; Hézode C; Rosa I; Renard P; Mohamed MK; Bonnard P; Izopet J; Mallet V; Pol S; Albert ML; Fontanet A
    J Hepatol; 2014 Oct; 61(4):770-6. PubMed ID: 24905490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of non-genotype 1 hepatitis C virus patients.
    Mangia A; Mottola L
    Curr Gastroenterol Rep; 2012 Feb; 14(1):87-93. PubMed ID: 22113745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
    Rivero-Juárez A; Camacho Espejo A; Perez-Camacho I; Neukam K; Caruz A; Mira JA; Mesa P; García-Lázaro M; Torre-Cisneros J; Pineda JA; Rivero A
    J Antimicrob Chemother; 2012 Jan; 67(1):202-5. PubMed ID: 21990051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
    Kobayashi M; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Hosaka T; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Miyakawa Y; Kumada H
    J Gastroenterol; 2012 May; 47(5):596-605. PubMed ID: 22438096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.